ArticleNature immunology2023
The GPCR-Gα
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 73 citations in OpenAlex.
- Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.Nature aging · 2025Trial
- The update of prostaglandin E2 receptor subtype 4 (EP4) in inflammatory diseases.Genes & diseases · 2026Review
- Article
- Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Inhibitory probes for spatiotemporal analysis of GαNature chemical biology · 2026Article
- Cancer Neuroscience: From Local Neuro-Immune Microenvironments to Systemic Brain-Body Circuitry.MedComm · 2026Review
- Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Neural regulation of tumor immunity: emerging opportunities to enhance cancer immunotherapy.Experimental & molecular medicine · 2026Review
- β-Adrenergic receptors as immunomodulators in T cells: mechanisms of neuroimmune crosstalk and pathophysiological implications.Molecular medicine (Cambridge, Mass.) · 2026Review
- Immune checkpoint crosstalk between LAG-3 and CD39/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies.Journal of the Egyptian National Cancer Institute · 2026Review
- Structured water molecules drive activation and G protein selectivity in the GPR174 receptor.PLoS biology · 2026Article
- Enhancement of a nuclear factor of activated T cells (NFAT) reporter for the study of G protein-coupled receptors.Communications biology · 2026Article
- Genome-wide CRISPR screens in primary human natural killer cells identify countermeasures against immunosuppressive environment.Nature communications · 2026Article
- The COX2-PGEbioRxiv : the preprint server for biology · 2026Article
- Molecular Markers Distinguishing Early-Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions.Experimental dermatology · 2026Article
- CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma.Cell reports · 2026Article
- Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner.Clinical and experimental immunology · 2026Article
- GNA15 as a regulator of tumor-immune crosstalk: oncogenic signaling, microenvironmental remodeling, and implications for targeted immunotherapy.Frontiers in immunology · 2026Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 9 institutions in 2 countries.
Victoria H Wu *Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Bryan S Yung *Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Farhoud FarajiDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-5078-813X
Robert Saddawi-KonefkaDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9936-1695
Zhiyong WangUCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Alexander T WenzelUCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-2056-2938
Miranda J SongUCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4448-277X
Meghana S PagadalaDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Lauren M ClubbDepartment of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Joshua ChiouBiomedical Sciences Graduate Studies Program, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4618-0647
Sanju SinhaCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Marin MaticLaboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Pisa, Italy.ORCID http://orcid.org/0000-0003-1449-8797
Francesco RaimondiLaboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Pisa, Italy.
Thomas S HoangDepartment of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1282-734X
Rebecca BerdeauxDepartment of Integrative Biology and Pharmacology, McGovern Medical School at UT Health Houston and CellChorus INC, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9929-1711
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-2771-5992
Ramiro Iglesias-BartolomeLaboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0792-1254
Hannah CarterUCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1729-2463
Eytan RuppinCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jill P MesirovUCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
J Silvio GutkindDepartment of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. sgutkind@health.ucsd.edu.ORCID http://orcid.org/0000-0002-5150-4482
University of California San Diego · USNational Institutes of Health · USScuola Normale Superiore · ITNational Cancer Institute · USPfizer (United States) · USSoutheastern University · USThe University of Texas Health Science Center at Houston · USUC San Diego Health System · USUniversity of Pittsburgh · US
Funding
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5MUsing Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY, KROGAN, NEVAN J · 2017 to 2021
$10.9MSan Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7MSignaling pathways regulating stem cell fate decisionsZIABC011763 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI IGLESIAS-BARTOLOME, RAMIRO · 2017 to 2025
$7.5MPredoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5MStimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6MGenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer ResearchU24CA248457 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2020 to 2024
$4.6MSupporting and evolving Gene Set Enrichment Analysis and the Molecular Signatures Database for cancer researchU24CA220341 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2018 to 2022
$3.4MRegulation of glucose utilization by skeletal muscle SIK1R01DK092590 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BERDEAUX, REBECCA L · 2011 to 2021
$3.3MCo-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCCR01CA247551 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2020 to 2024
$2.5MTargeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3MG-protein-coupled receptor signaling in cancer development and treatmentZIABC011764 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI IGLESIAS-BARTOLOME, RAMIRO · 2017 to 2022
$1.9MIntramural NIH HHS ZIA BC011764NCI NIH HHS 1F31CA250488-01NCI NIH HHS F31 CA250488NCI NIH HHS F31 CA257344NCI NIH HHS F31CA257344NCI NIH HHS R01 CA247551NCI NIH HHS R01CA247551NCI NIH HHS T32 CA067754NCI NIH HHS U24 CA220341NCI NIH HHS U24CA220341NCI NIH HHS U24 CA248457NCI NIH HHS U24CA248457NCI NIH HHS U54 CA209891NCIRD CDC HHS U54CA209891NIAMS NIH HHS R01 AR072368NIAMS NIH HHS R01-AR-072368NIDCR NIH HHS 1F31DE031961-01NIDCR NIH HHS F31 DE031961NIDCR NIH HHS F32 DE029990NIDCR NIH HHS F32DE029990-01NIDCR NIH HHS R01 DE026870NIDCR NIH HHS R01DE026870NIDCR NIH HHS U01 DE028227NIDDK NIH HHS R01 DK092590NIDDK NIH HHS R01-DK092590NIDDK NIH HHS T32 DK007752NIGMS NIH HHS T32 GM007752NLM NIH HHS T15 LM011271NLM NIH HHS T15LM011271
Abstract
Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve durable responses. G-protein-coupled receptors (GPCRs) are the most intensively studied drug targets but are underexplored in immuno-oncology. Here, we cross-integrated large singe-cell RNA-sequencing datasets from CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAnimalsImmunotherapyMiceMice, TransgenicSignal TransductionTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.